Revised cutoff values of ALT and HBV DNA level can better differentiate HBeAg (-) chronic inactive HBV patients from active carriers

Virology Journal

Volumn 8, Issue , 2011, Pages

  Ijaz, Bushra ^a   Ahmad, Waqar ^a   Javed, Fouzia T ^b   Gull, Sana ^a   Hassan, Sajida ^a  

^a UNIVERSITY OF THE PUNJAB   (Pakistan)

^b JINNAH HOSPITAL   (Pakistan)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; HEPATITIS B(E) ANTIGEN; VIRUS DNA;

ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; CHRONIC ACTIVE HEPATITIS; COHORT ANALYSIS; CROSS-SECTIONAL STUDY; DIAGNOSTIC TEST ACCURACY STUDY; DIAGNOSTIC VALUE; DIFFERENTIAL DIAGNOSIS; EVALUATION; FEMALE; HEPATITIS B; HEPATITIS B VIRUS; HUMAN; MAJOR CLINICAL STUDY; MALE; PAKISTAN; PERFORMANCE; REFERENCE VALUE; SCREENING TEST; SENSITIVITY AND SPECIFICITY; SEX RATIO; VIRUS CARRIER; VIRUS LOAD; BLOOD; DIAGNOSIS, MEASUREMENT AND ANALYSIS; HETEROZYGOTE; METHODOLOGY;

HEPATITIS B VIRUS; NUCLEOPOLYHEDROVIRUS;

ADULT; ALANINE TRANSAMINASE; ASPARTATE AMINOTRANSFERASES; CARRIER STATE; CLINICAL LABORATORY TECHNIQUES; CROSS-SECTIONAL STUDIES; DIAGNOSIS, DIFFERENTIAL; DNA, VIRAL; FEMALE; HEPATITIS B E ANTIGENS; HEPATITIS B, CHRONIC; HUMANS; MALE; VIRAL LOAD;

EID: 79951949134     PISSN: None     EISSN: 1743422X     Source Type: Journal    
DOI: 10.1186/1743-422X-8-86     Document Type: Article

References (38)

1. Prevalence and geographic distribution of Hepatitis C Virus genotypes in Indian patient cohort. S Narahari A Juwle S Basak D Saranath, Infect Genet Evol 2009 9 643 645 10.1016/j.meegid.2009.04.001 19460332
2. Searching for chronic hepatitis B patients in a low prevalence area - role of racial origin. SK Ono-Nita FJ Carrilho RA Cardoso ME Nita LC da Silva, BMC Fam Pract 2004 5 7 10.1186/1471-2296-5-7 15084223
3. Quantitative hepatitis B virus DNA testing for the early prediction of the maintenance of response during lamivudine therapy in patients with chronic hepatitis B. M Buti F Sanchez M Cotrina R Jardi F Rodriguez R Esteban J Guardia, J Infect Dis 2001 183 1277 1280 10.1086/319677 11262212 (Pubitemid 32281569)
4. Identification of different states of hepatitis B virus infection with a quantitative PCR assay. HH Kessler S Preininger E Stelzl E Daghofer BI Santner E Marth H Lackner RE Stauber, Clin Diagn Lab Immunol 2000 7 298 300 10702509 (Pubitemid 30132128)
5. Quantification and genotyping in management of chronic hepatitis B and C. F Zoulim, Virus Res 2002 82 45 52 10.1016/S0168-1702(01)00386-0 11885949 (Pubitemid 34273710)
6. Confirmatory testing of hepatitis C virus-positive enzyme immunoassay results in limited-resource countries: should it be attempted? KE Nelson H Shan, Transfusion 2008 48 1239 1244 10.1111/j.1537-2995.2008.01696.x 18373499 (Pubitemid 351793506)
7. AS Lok BJ McMahon B Chronic hepatitis, Hepatology 2007 45 507 539 10.1002/hep.21513 17256718
8. Evaluation of abnormal liver-enzyme results in asymptomatic patients. DS Pratt MM Kaplan, N Engl J Med 2000 342 1266 1271 10.1056/NEJM200004273421707 10781624 (Pubitemid 30235957)
9. Diagnosis and monitoring of hepatic injury. I. Performance characteristics of laboratory tests. DR Dufour JA Lott FS Nolte DR Gretch RS Koff LB Seeff, Clin Chem 2000 46 2027 2049 11106349
10. AGA technical review on the evaluation of liver chemistry tests. RM Green S Flamm, Gastroenterology 2002 123 1367 1384 10.1053/gast.2002.36061 12360498
11. Abundance of immunologically active alanine aminotransferase in sera of liver cirrhosis and hepatocellular carcinoma patients. HJ Kim SW Oh DJ Kim EY Choi, Clin Chem 2009 55 1022 1025 10.1373/clinchem.2008.102996 19264859
12. Updated definitions of healthy ranges for serum alanine aminotransferase levels. D Prati E Taioli A Zanella E Della Torre S Butelli E Del Vecchio L Vianello F Zanuso F Mozzi S Milani D Conte M Colombo, Ann Intern Med 2002 137 1 10 12093239
13. AST/ALT ratio predicts cirrhosis in patients with chronic hepatitis C virus infection. SG Sheth SL Flamm FD Gordon S Chopra, Am J Gastroenterol 1998 93 44 48 10.1111/j.1572-0241.1998.044-c.x 9448172 (Pubitemid 29065511)
14. Hepatic ultrasonic changes in workers exposed to perchloroethylene. CA Brodkin W Daniell H Checkoway D Echeverria J Johnson K Wang R Sohaey D Green C Redlich D Gretch, et al. Occup Environ Med 1995 52 679 685 10.1136/oem.52.10.679 7489059
15. Assessment of liver fibrosis in co-infected patients. TB Kelleher N Afdhal, J Hepato 2006 44 126 S131 10.1016/j.jhep.2005.11.026 (Pubitemid 43053888)
16. Normal serum aminotransferase concentration and risk of mortality from liver diseases: prospective cohort study. HC Kim CM Nam SH Jee KH Han DK Oh I Suh, BMJ 2004 328 983 10.1136/bmj.38050.593634.63 15028636
17. Serum activity of alanine aminotransferase (ALT) as an indicator of health and disease. WR Kim SL Flamm AM Di Bisceglie HC Bodenheimer, Hepatology 2008 47 1363 1370 10.1002/hep.22109 18366115 (Pubitemid 351547922)
18. Risk of hepatocellular carcinoma in hepatitis B and prevention through treatment. M Sherman, Cleve Clin J Med 2009 76 6 9 10.3949/ccjm.76.s3.02 19465708
19. Relationship of clinical and virological factors with hepatitis activity in hepatitis B e antigen-negative chronic hepatitis B virus-infected patients. JJ Sung HL Chan ML Wong CH Tse SC Yuen JS Tam NW Leung, J Viral Hepat 2002 9 229 234 10.1046/j.1365-2893.2002.00352.x 12010512 (Pubitemid 36005522)
20. Prognostic determinants for chronic hepatitis B in Asians: therapeutic implications. MF Yuen HJ Yuan DK Wong JC Yuen WM Wong AO Chan BC Wong KC Lai CL Lai, Gut 2005 54 1610 1614 10.1136/gut.2005.065136 15871997 (Pubitemid 41531781)
21. Evaluation of impact of serial hepatitis B virus DNA levels on development of hepatocellular carcinoma. HL Chan VW Wong GL Wong AM Chim LH Lai JJ Sung, J Clin Microbiol 2009 47 1830 1836 10.1128/JCM.00029-09 19386857
22. Lower baseline ALT cut-off values and HBV DNA levels better differentiate HBeAg- chronic hepatitis B patients from inactive chronic carriers. N Assy Z Beniashvili A Djibre G Nasser M Grosovski W Nseir, World J Gastroenterol 2009 15 3025 3031 10.3748/wjg.15.3025 19554656
23. When to start and stop hepatitis B treatment: can one set of criteria apply to all patients regardless of age at infection? B Degertekin AS Lok, Ann Intern Med 2007 147 62 64 17606963 (Pubitemid 351664635)
24. Natural history of chronic hepatitis B: special emphasis on disease progression and prognostic factors. G Fattovich F Bortolotti F Donato, J Hepatol 2008 48 335 352 10.1016/j.jhep.2007.11.011 18096267
25. Diagnosis and monitoring of hepatic injury. I. Performance characteristics of laboratory tests. DR Dufour JA Lott FS Nolte DR Gretch RS Koff LB Seeff, Clin Chem 2000 46 2027 2049 11106349
26. Abundance of immunologically active alanine aminotransferase in sera of liver cirrhosis and hepatocellular carcinoma patients. HJ Kim SW Oh DJ Kim EY Choi, Clin Chem 2009 55 1022 1025 10.1373/clinchem.2008.102996 19264859
27. Baseline predictors of virological response for chronic hepatitis B patients. XJ Wu Y Wang J Chen GQ Wang, World J Gastroenterol 2009 15 4311 4315 10.3748/wjg.15.4311 19750575
28. A treatment algorithm for the management of chronic hepatitis B virus infection in the United States: 2008 update. EB Keeffe DT Dieterich SH Han IM Jacobson P Martin ER Schiff H Tobias, Clin Gastroenterol Hepatol 2008 6 1315 1341 10.1016/j.cgh.2008.08.021 18845489
29. Diagnostic value of serum bile acids and routine liver function tests in hepatobiliary diseases. Sensitivity, specificity, and predictive value. R Ferraris G Colombatti MT Fiorentini R Carosso W Arossa PM de la, Dig Dis Sci 1983 28 129 136 10.1007/BF01315142 6825534 (Pubitemid 13190092)
30. Normal serum aminotransferase concentration and risk of mortality from liver diseases: prospective cohort study. HC Kim CM Nam SH Jee KH Han DK Oh I Suh, BMJ 2004 328 983 10.1136/bmj.38050.593634.63 15028636
31. Relation between laboratory test results and histological hepatitis activity in individuals positive for hepatitis B surface antigen and antibodies to hepatitis B e antigen. F ter Borg FJ ten Kate HT Cuypers A Leentvaar-Kuijpers J Oosting PM Wertheim-van Dillen P Honkoop MC Rasch RA de Man J van Hattum RA Chamuleau HW Reesink EA Jones, Lancet 1998 351 1914 1918 10.1016/S0140-6736(97) 09391-4 9654258 (Pubitemid 28297447)
32. Significance of HBV DNA Levels in Liver Histology of HBeAg and Anti-HBe Positive Patients with Chronic Hepatitis B. MF Yuen IO Ng ST Fan HJ Yuan DK Wong JC Yuen SS Sum AO Chan CL Lai, Am J Gastroenterol 2004 99 20327 10.1111/j.1572-0241.2004.40440.x (Pubitemid 39421251)
33. Significance of hepatitis B viremia levels determined by a quantitive polymerase chain assay in patient with hepatitis B e antigen negative chronic hepatitis B virus infection. EK Manesis GV Papatheodoridis V Sevastianos E Cholongitas C Papaioannou SJ Hadziyannis, Am J Gastroentrol 2003 98 2261 2267 (Pubitemid 37305368)
34. Hepatitis B virus DNA in anti- HBe-positive asymptomatic carriers. Y Seo S Yoon M Nakaji Y Yano H Nagano T Ninomiya Y Hayashi M Kasuga, Intervirology 2003 46 43 49 10.1159/000068123 12566698 (Pubitemid 36173476)
35. A Threshold HBV DNA Level for Discriminating Patients with Hepatitis B e Antigen-Negative Chronic Hepatitis B from Inactive Carriers. ES Kim YS Seo Keum JH Kim H An HJ Yim YS Kim YT Jeen HJ Chun SH Um CD Kim HS Ryu HS Lee, Hep Monthly 2011
36. Immune response to hepatitis B virus proteins: relevance of the murine model. DR Milich, Semin Liver Dis 1991 11 93 112 10.1055/s-2008-1040428 1832237
37. Viral genotype and hepatitis B virus DNA levels are correlated with histological liver damage in HBeAg-negative chronic hepatitis B virus infection. HL Chan VW Wong GL Wong AM Chim LH Lai JJ Sung, Am J Gastroenterol 2002 97 406 412 10.1111/j.1572-0241.2002.05478.x 11866280 (Pubitemid 34160768)
38. Correlation between serum transaminase activity and virus load among patients with chronic liver disease type B. H Sakugawa H Nakasone T Nakayoshi Y Kawakami T Yamashiro T Maeshiro F Kinjo A Saito, Hepatol Res 2001 21 159 168 10.1016/S1386-6346(01)00085-7 11551836 (Pubitemid 32899086)